The economics newspaper Expansión Catalunya has echoed the forthcoming publication of the results of a clinical assay of the MAF-Test, a diagnostic test for breast cancer patients developed by Inbiomotion, a spin-off from IRB Barcelona set up in 2010 by the researcher Roger Gomis. The results are expected to be out in November. This test may have the capacity to identify those breast cancer patients who would benefit from treatment with bisphosphonates, a class of drugs used to treat non-metastatic breast cancer, but whose administration can in many cases be counterproductive. If the results are positive, it is hoped that this test will reduce mortality from the disease by 31%.
The funded project will address the development of metastasis in breast cancer.
The grant, which is specifically for research into breast cancer, has been given by the foundation, in collaboration with Mango.
Fero is a private foundation that promotes translational cancer research in Spain.
On 19 October, World Breast Cancer Day is celebrated to remember the commitment of the entire society in the fight against this disease -the most common tumour in western women.
La Opinión de Zamora has published an article summarising the days of oncological research organised by the United Association against Cancer Toro and its Alfoz (AUCCTA) and in which Angel R. Nebreda, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) participated.
